Sign In

Scott Morenstein

Managing Director, Head of Life Sciences Public and Private Investing at CAM Capital

Scott Morenstein is currently a Managing Director in Blackstone Multi-Asset Investing (BXMA), a position he has held since joining Blackstone in 2022.2 Prior to this, he served as Managing Director at CAM Capital from November 2013 to 2022, where he led biotechnology investing.12

Morenstein's career in finance and healthcare spans over two decades. His previous roles include:

  • Managing Director at Valence Advantage Life Sciences Fund (January 2012 - November 2013)2
  • Principal at Caxton Advantage Venture Partners (2007 - 2011)2
  • Investment Banking Associate and founding member of Seaview Securities (2003 - 2005)2
  • Healthcare Investment Banker and Equity Research Analyst at Lehman Brothers (2000 - 2002)2

He has served on the boards of several biopharmaceutical companies, including:

  • Molecular Templates, Inc. (Nasdaq: MTEM) since July 20171
  • Antios Therapeutics since November 20181
  • Primmune Therapeutics since March 20201
  • Avenge Bio since December 20211

Morenstein holds an M.B.A. from Harvard Business School and a B.A. from the University of Pennsylvania with a degree in the Biological Basis of Behavior.12

Highlights

Oct 28 · blackstone.com
Scott Morenstein - Blackstone
Scott Morenstein - Blackstone

Related Questions

What are some of the notable investments Scott Morenstein has led at CAM Capital?
How did Scott Morenstein transition from investment banking to venture capital?
What is the investment strategy at CAM Capital under Scott Morenstein's leadership?
What companies has Scott Morenstein served on the board of directors for?
How has Scott Morenstein's background in biology influenced his investment decisions?
Scott Morenstein
Scott Morenstein, photo 1
Scott Morenstein, photo 2
Add to my network

Location

Old Greenwich, Connecticut, United States